Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Columbia Expands Prochieve's Reach Beyond Infertility Market With Ascend License Agreement

This article was originally published in The Pink Sheet Daily

Executive Summary

Ascend’s 100 reps will detail the progesterone gel to over 14,000 women’s health physicians.

You may also be interested in...

Vivus Gets FDA Approval For Evamist Estradiol Spray

Approval triggers $140 million payment from KV Pharmaceutical, which licensed the product in March.

Columbia Labs' Prochieve Could Address $150 Million To $300 Million Preterm Birth Market

Firm anticipates sNDA approval for progesterone vaginal gel product in recurrent preterm birth as early as 2008.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts